Skip to main content
. 2016 Dec 20;7(1):35–43. doi: 10.1002/2211-5463.12147

Figure 5.

Figure 5

T0901317 sensitizes gefitinib by inhibiting the PI3K/Akt signal pathway. (A) A549 cells were treated for 3 days with gefitinib (5 μm) alone, T0901317 (5 μm) alone, or the two drugs in combination. Cells were lyzed and the indicated proteins were detected by western blot. (B) Western blot analysis was performed using the indicated antibodies after A549 cells were treated with 5 μm T0901317 for different days.